Indonesia, Singapore To Enhance Military Cooperation To Support Regional Stability

Indonesia and Singapore have agreed to establish an annual defence forum, to strengthen their military partnership, in order to support stability in the Southeast Asia region, Indonesian Defence Minister, Prabowo Subianto, said yesterday.

Subianto said that, the forum for defence partnership committee, which would have a military sub-committee in it, was expected to be a place for both countries to further discuss military cooperation in various fields, and to create new areas of cooperation.

The plan was conveyed yesterday during a visit by Singapore’s Chief of Defence Force, Lieutenant-General Melvyn Ong to Jakarta, during his close-door meeting with Subianto.

“Indonesia fully supports the strengthening of our close military cooperation with Singapore that we have built, based on the principles of equality, mutual benefit and full respect for each country’s sovereignty and territorial integrity, as well as, international laws,” Subianto noted.

He also said, the military partnership between the two nations has become more significant, after Indonesia ratified last Dec, the Defence Cooperation Agreement between Indonesia and Singapore, a deal which aims to boost both countries’ defence capabilities through security dialogues, intelligence sharing, scientific cooperation and joint military exercises.

 

Source: NAM News Network

 

Azerbaijani currency rates for February 28

BAKU, Azerbaijan, February 28. The official exchange rate of the US dollar and euro against Azerbaijani manat as of February 28, 2023, is set at 1.7 and 1.7999 manat, respectively, Trend reports via Central Bank of Azerbaijan (CBA).

The manat rate to other global currencies for Tuesday according to the CBA:

Currencies
1 US dollar USD 1.7
1 Euro EUR 1.7999
1 Australian dollar AUD 1.1437
1 Argentine peso ARS 0.0086
1 Belarus ruble BYN 0.6735
1 Brazil real BRL 0.3268
1 UAE dirham AED 0.4628
1 South African rand ZAR 0.0922
100 South Korean won KRW 0.1285
1 Czech koruna CZK 0.0761
1 Chilean peso CLP 0.2042
1 Chinese yuan CNY 0.245
1 Danish krone DKK 0.2418
1 Georgian lari GEL 0.6481
1 Hong Kong dollar HKD 0.2166
1 Indian rupee INR 0.0206
1 British pound GBP 2.0478
100 Indonesian rupiah IDR 0.0112
100 Iranian rials IRR 0.004
1 Swedish krona SEK 0.1633
1 Swiss franc CHF 1.815
1 Israeli shekel ILS 0.4644
1 Canadian dollar CAD 1.2514
1 Kuwaiti dinar KWD 5.5361
1 Kazakh tenge KZT 0.0038
1 Kyrgyz som KGS 0.0195
100 Lebanese pound LBP 0.0113
1 Malaysian ringgit MYR 0.3791
1 Mexican peso MXN 0.0925
1 Moldovan leu MDL 0.0902
1 Egyptian pound EGP 0.0555
1 Norwegian krone NOK 0.1641
100 Uzbek soum UZS 0.015
1 Polish zloty PLN 0.3817
1 Russian ruble RUB 0.0228
1 Singapore dollar SGD 1.2603
1 Saudi riyal SAR 0.453
1 SDR (Special Drawing Rights of IMF) XDR 2.2547
1 Turkish lira TRY 0.09
1 Taiwan dollar TWD 0.0556
1 Tajik somoni TJS 0.1653
1 New Turkmen manat TMT 0.4857
1 Ukrainian hryvnia UAH 0.0462
100 Japanese yen JPY 1.2474
1 New Zealand dollar NZD 1.0462

 

 

Source: TREND News Agency

 

Iranian currency rates for February 28

BAKU, Azerbaijan, February 28. The Central Bank of Iran (CBI) announced an official rate of foreign currencies on February 28, Trend reports referring to CBI.

According to the currency exchange rate of the Central Bank of Iran, 22 currencies increased and 15 have decreased in price, compared to February 27.

According to CBI, $1 equals 42,000 Iranian rials and 1 euro equals 44,499 rials.

Currency Iranian rial on February 28 Iranian rial on February 27
1 US dollar USD 42,000 42,000
1 British pound GBP 50,549 50,167
1 Swiss franc CHF 44,794 44,655
1 Swedish krona SEK 4,034 3,998
1 Norwegian krone NOK 4,056 4,039
1 Danish krone DKK 5,979 5,951
1 Indian rupee INR 508 507
1 UAE dirham AED 11,437 11,437
1 Kuwaiti dinar KWD 136,748 136,549
100 Pakistani rupees PKR 16,145 16,149
100 Japanese yens JPY 30,838 30,725
1 Hong Kong dollar HKD 5,354 5,351
1 Omani rial OMR 109,085 109,110
1 Canadian dollar CAD 30,935 30,845
1 New Zealand dollar NZD 25,887 25,839
1 South African rand ZAR 2,280 2,284
1 Turkish lira TRY 2,224 2,226
1 Russian ruble RUB 561 554
1 Qatari riyal QAR 11,539 11,539
100 Iraq dinars IQD 2,879 2,878
1 Syrian pound SYP 17 17
1 Australian dollar AUD 28,261 28,328
1 Saudi riyal SAR 11,200 11,200
1 Bahraini dinar BHD 111,700 111,701
1 Singapore dollar SGD 31,172 31,100
100 Bangladeshi takas BDT 39,392 39,516
10 Sri Lankan rupees LKR 1,157 1,152
1 Myanmar kyat MMK 21 21
100 Nepalese rupees NPR 31,725 31,645
1 Libyan dinar LYD 8,680 8,712
1 Chinese yuan CNY 6,048 6,062
100 Thai baths THB 119,899 120,110
1 Malaysian ringgit MYR 9,398 9,472
1,000 South Korean wons KRW 31,848 31,934
1 Jordanian dinar JOD 59,239 59,239
1 euro EUR 44,499 44,258
100 Kazakh tenge KZT 9,389 9,349
1 Georgian lari GEL 16,033 15,955
1,000 Indonesian rupiahs IDR 2,755 2,763
1 Afghan afghani AFN 473 473
1 Belarus ruble BYN 16,756 16,634
1 Azerbaijani manat AZN 24,714 24,703
100 Philippine pesos PHP 76,768 76,527
1 Tajik somoni TJS 3,849 3,851
1 Turkmen manat TMT 11,990 11,968

In Iran, the official exchange rate is used for the import of some essential products.

SANA system is a system introduced by the Central Bank of Iran to the currency exchange offices, where the price of 1 euro is 323,434 rials, and the price of $1 is 306,930 rials.

NIMA is a system intended for the sale of a certain percentage of the foreign currency gained from export.

The price of 1 euro in this system is 300,325 rials, and the price of $1 is 285,000 rials.

On the black market, $1 is worth about 581,000-584,000 rials, while 1 euro is worth about 615,000-618,000 rials.

 

 

Source: TREND News Agency

Canon Medical Extends Clinically Intelligent AI-driven Enterprise Platform to include Pathology Through Partnership with Tribun Health

MINNETONKA, Minn., Feb. 28, 2023 (GLOBE NEWSWIRE) — Canon Medical Informatics, Inc. has extended its Enterprise Imaging (EI) suite of solutions to include pathology through its partnership with Tribun Health. This provides new capability for healthcare organizations to efficiently include pathology into their enterprise imaging plans as part of their precision informatics roadmaps. Canon Medical offers healthcare organizations an all in one suite of solutions and one comprehensive partnership for your most imaging-intensive departments, such as radiology, cardiology, endoscopy, and now pathology.

“Our relationship with Tribun Health demonstrates our commitment to be a clinical decision partner by expanding the clinical breadth of our Enterprise Imaging solutions to drive efficiency and seamless access to critical multi-modal clinical information for all clinicians caring for patients,” says Jim Litterer, President & CEO of Canon Medical Informatics. “Our future together is part of Canon Medical’s overall strategy to consolidate the complex and emerging specialties that are the foundation for personalized medicine.”

Delivering a common, clinically intelligent platform across complex, multi-site institutions to achieve common efficiencies for diagnosis, treatment planning and long-term patient management has been the core of Canon Medical Enterprise solutions. Serving up relevant, efficient access to imaging data optimally from its Enterprise Platform sets Canon Medical apart from solutions that segregate their departmental solutions from their VNAs. Canon Medical’s EI suite combines disease-centric solutions to promote sub-specialty collaboration. Tribun Health’s KLAS-leading CaloPix solution was the perfect intelligent extension with same cultural fit to Canon Medical and its solutions and services.

“Our partnership extends our reach to deliver comprehensive diagnostic and AI-based analysis to pathologists and increases the collaboration they have with their clinical partners,” says Jean-Francois Pomeral, CEO of Tribun Health. “Our KLAS-leading solution coupled with Canon Medical’s Enterprise Imaging solutions centrally positions the digital transformation of diagnosis with oncologists and clinicians alike.”

Canon Medical solutions power some of the largest, most complex, and dynamic organizations around the world.

About Tribun Health:

Tribun Health is a leading provider of AI-powered digital pathology solutions, transforming the way pathologists diagnose and treat diseases. Our advanced technology, combined with our clinical and informatics expertise, delivers unparalleled accuracy, speed, and efficiency in pathology diagnosis.

We have been recognized as a two-time Best in KLAS award winner (2022 & 2023) for our excellence in customer satisfaction and continue to be recognized for our innovative approach to digital pathology and commitment to customer success.

Tribun Health is a pioneer in digital pathology workflow solutions with image acquisition (Macro), image storage, web-based image management system (IMS), image analysis using AI-powered deep and machine learning algorithms, remote case sharing with peer review and reporting.

Visit our website at www.tribun.health to learn more about our end-to-end digital pathology suite.

About Canon Medical Informatics, Inc.

Canon Medical Informatics, part of Canon Medical Systems, offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical, we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life. For more information, visit the Canon Medical website: https://global.medical.canon.

Made for Life is a trademark of Canon Medical Systems Corporation

For more information contact:
Zach Stenger
Canon Medical Informatics, Inc.
952-487-9534
zach.stenger@mi.medical.canon
us.medical.canon/hit

GlobeNewswire Distribution ID 8777916

Azerion publishes Interim Unaudited Q4 and FY 2022 Results

Delivery on 2022 targets with profitable growth outlook

Highlights of Q4 2022

  • Delivery of 2022 targets. Full year 2022 Net revenue of EUR 453 million (guidance of at least EUR 450 million), with Adjusted EBITDA of EUR 52 million (guidance of at least EUR 50 million), reflecting almost 10% organic growth in 2022.
  • Record performance in the Platform segment, driving Q4 2022 Net revenue of EUR 149 million, up from EUR 126 million in Q4 2021. Adjusted EBITDA of EUR 22 million, up by 14% compared to Q4 2021, reflecting improved platform efficiencies.
  • 2023 outlook of around EUR 560 million Net revenue and at least EUR 75 million Adjusted EBITDA.
  • Highest direct sales results across the group, demonstrating the added value of local teams working hand in hand with clients to successfully advertise to their audiences.
  • Additional integrations with automated platforms such as Amazon DSP and Google Audience targeting, increasing our revenue from programmatic advertising.
  • Entered high-growth digital audio, enabling audio ad formats across the platform through the acquisition of Radionomy (Targetspot and Shoutcast).
  • Strengthened our position in the Metaverse by creating more partnerships with brands such as DB Sports and successfully selling out a collection of 1,300 unique rooms in Habbo X.

Selected Financial KPIs

Financial results (EURm) Q4 FY
Azerion Group1) 2022 2021 2022 2021
Net revenue 148.8 126.3 452.6 308.1
Gross profit 53.1 50.4 166.3 120.9
Operating profit / (loss) 8.9 5.4 (129.0) 8.4
Adjusted EBITDA 22.1 19.4 52.1 46.7
Net revenue growth % 17.8% 46.9%
Gross profit margin % 35.7% 39.9% 36.7% 39.2%
Adjusted EBITDA growth % 13.9% 11.6%
Adjusted EBITDA margin % 14.9% 15.4% 11.5% 15.2%

1) Reported figures relate to Azerion Group N.V. following the merger with Azerion Holding B.V.. See “Background information” for more details

Co-CEO Umut Akpinar said:

“This quarter we continued improving our Platform and expanding our geographical presence to gain market share and harvest the benefits of scale in 2023. We focused on helping our clients achieve better results for their campaigns through differentiated, engaging and innovative ad formats. We continued integrating our past acquisitions and optimising costs, and expect to generate annualised savings of over EUR 10 million in 2023. This strong performance has allowed us to achieve our financial targets for 2022 and gives us confidence to update our guidance for 2023 and beyond.”

Co-CEO Atilla Aytekin said:

“In 2022 we completed strategic acquisitions and simplified our reporting structure. Looking ahead, we will focus on growing our Platform capabilities, whilst balancing our growth with a prudent financial framework. We will remain actively working on our M&A pipeline and as we target a capital structure that is more aligned with market practice, we announced the intention to cancel the majority of our treasury shares. In addition, we will also increase our focus on deleveraging our balance sheet in 2023.

Financial overview

Net revenue

Net revenue for the quarter amounted to EUR 148.8 million, an increase of 17.8%, compared to Q4 2021, due to growth in the Platform segment. Full year 2022 Net revenue was EUR 452.6 million, compared to EUR 308.1 million in 2021.

Earnings

Adjusted EBITDA was EUR 22.1 million for the quarter compared to EUR 19.4 million in Q4 2021, an increase of 13.9%, driven by stronger contributions from the Platform segment, partially offset by lower Adjusted EBITDA from the Premium Games segment. Full year 2022 Adjusted EBITDA was EUR 52.1 million, compared to EUR 46.7 million in 2021.

The operating profit for the quarter amounted to EUR 8.9 million, compared to a profit of EUR 5.4 million in Q4 2021, reflecting various factors including increased Net revenue, contributions of acquisitions and reduced operating expenses.

Cash flow

Cash flow from operating activities in Q4 2022 was an inflow of  EUR 20.0 million, Cash flow from investing activities was an outflow of EUR 14.8 million, mainly due to acquisitions. Cash flow from financing activities totalled an outflow of  EUR 3.1 million. Full year 2022 cash flow from operating activities amounted to EUR 44.9 million, compared to EUR 24.0 million in 2021.

Capex

Azerion capitalizes development costs related to asset development, a core activity to support innovation in its platform. These costs primarily relate to developers’ time devoted to the development of games, platforms, and other new features. In Q4 2022 Azerion capitalized EUR 5.5 million, equivalent to 18.0% of gross personnel costs, which is broadly in line with previous quarters.

Financial position and financing

Our net interest-bearing debt*) amounted to EUR 176.1 million as of 31 December 2022, mainly comprising our outstanding bond loan with a nominal value of EUR 200 million (part of a total EUR 300 million framework) and lease liabilities with a balance of EUR 19.2 million less the cash and cash equivalents position of EUR 50.9 million.

Tax positions 

Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Management’s assessment is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits. At the moment of publication of this preliminary unaudited financial results report, the assessment of current and deferred tax positions have not been fully finalised and might be revised ahead of the publication of the Annual Report 2022.

*) As defined in section 1.1 of the Terms & Conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794. Please also refer to the Definitions section and the notes of this Interim Report for more information.

Segment information

Platform

Our Platform segment includes advertising, casual games distribution and e-Commerce, which are fully integrated through our technology. It generates Net revenue mainly by displaying digital advertisements in both game and non-game content, as well as selling and distributing AAA games through our e-commerce channels. Platform is also integrated with our Premium Games segment, leveraging inter-segment synergies.

Platform – Selected Financial KPIs

Financial results (EURm) Q4 FY
Platform 2022 2021 2022 2021
Net revenue 124.7 101.4 363.5 234.5
Gross profit 41.0 34.0 121.4 78.0
Operating profit / (loss) 7.4 2.7 (6.5) 2.3
Adjusted EBITDA 17.0 11.5 35.0 26.6
Net revenue growth % 23.0% 55.0%
Gross profit margin % 32.9% 33.5% 33.4% 33.3%
Adjusted EBITDA growth % 47.8% 31.6%
Adjusted EBITDA margin % 13.6% 11.3% 9.6% 11.3%

Platform Net revenue was EUR 124.7 million in Q4 2022, an increase of 23.0% compared to Q4 2021, mainly due to acquisitions as well as organic growth.

Adjusted EBITDA was EUR 17.0 million in Q4 2022, increasing by 47.8% compared to Q4 2021, primarily driven by higher Net revenue and increased platform efficiency.

Results benefited from increased user engagement levels, with users spending more time playing casual games, as well as enhanced monetisation across the portfolio. In addition, we have grown our casual games distribution portfolio during Q4 2022, adding approximately 497 new titles and 493 new publisher partners.

Advertising – Selected Operational KPIs 

Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022
Avg. Digital Ads Sold per Month (bn) 10.9 9.9 9.5 9.6 10.7
Advertising auction platform (bn) 4.5 4.1 4.3 4.3 5.4
Publisher monetisation services (bn) 6.4 5.8 5.2 5.3 5.3
Avg. Gross Revenue per Million Optimised Ad Requests from advertising auction platform (EUR) 12.9 8.6 9.1 11.2 16.7
  • The Average number of digital ads sold per month (paid impressions) decreased to 10.7 billion from 10.9 billion in Q4 2021, reflecting an increase of the average ad price.
  • The Average gross revenue per million processed ad requests was EUR 16.7 in Q4 2022, compared to EUR EUR 12.9 in Q4 2021, demonstrating our ability to manage our advertising auction platform efficiently and profitably, even against the continued challenging macro-economic environment.

Average digital ads sold per month do not include volumes from past acquisitions that are not yet fully integrated. As of this quarter, the reported numbers include the following previous acquisitions: advertising auction platforms Improve Digital, Admoove, Delta Projects and Infinia, as well as publisher monetisation services Headerlift, Pubgalaxy, Sublime, Inskin, Strossle, Keymobile, Madvertise and Quantum.

Average gross revenue per million ad requests has been revised to exclude ad requests that are rejected before entering our advertising auction platform Improve Digital. As a result this KPI has been renamed as Average gross revenue per million processed ad requests.

Premium Games

Our Premium Games segment includes social games and metaverse, comprising nine premium game titles. The segment generates revenue mainly by offering users the ability to make in-game purchases for extra features and virtual goods to enhance their gameplay experience. The aim of this segment is to stimulate social interaction among players and build communities, offering an extended value proposition to advertisers and generating cross-selling opportunities with the Platform segment.

Premium Games – Selected Financial KPIs

Financial results (EURm) Q4 FY
Premium Games 2022 2021 2022 2021
Net revenue 24.1 25.0 89.1 73.6
Gross profit 12.1 16.4 44.9 42.8
Operating profit / (loss) 1.8 2.6 2.1 6.0
Adjusted EBITDA 5.1 7.8 17.1 19.8
Net revenue growth % (3.6)% 21.1%
Gross profit margin % 50.2% 65.6% 50.4% 58.2%
Adjusted EBITDA growth % (34.6)% (13.6)%
Adjusted EBITDA margin % 21.2% 31.2% 19.2% 26.9%

Premium Games Net revenue in Q4 2021 benefited from the ongoing commission related to secondary market sales of the Habbo NFTs launched in September 2021. Excluding this impact, Net revenue of EUR 24.1 million in Q4 2022 was at a similar level as in Q4 2021.

Adjusted EBITDA was EUR 5.1 million in Q4 2022, a decrease of 34.6% compared to Q4 2021, reflecting lower Net revenue, absence of NFT trail commission margin and higher marketing and user acquisition costs.

Premium Games – Selected Operational KPIs 

Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022
Avg. Time in Game per Day (min) 80 81 80 80 79
Avg. DAUs (thousands) 599 607 569 556 559
Avg. ARPDAU (EUR) 0.42 0.38 0.40 0.42 0.45
  • The Average time in game per day from our Premium Games players remained at a similar level as in Q4 2021.
  • The Average daily active users (DAUs) decreased by almost 7% compared to Q4 2021, reflecting a normalisation of Covid-19-induced elevated levels of users.
  • The Average revenue per daily active user (ARPDAU) increased by more than 7% compared to Q4 2021, primarily driven by new features and events that enhanced theuser gameplay experience.

Other

Reporting segment Other contained in Q4 an operating loss of EUR 0.3 million, mainly related to De-SPAC expenses (FY 2022: a loss of EUR 124.6 million, mainly related to De-SPAC related expenses not allocated to the Platform or Premium Games segments). Those costs impact the reported operating profit/loss, but are removed from Adjusted EBITDA.

Outlook

Net revenue for 2023 is expected to be around EUR 560 million, with expected annual growth thereafter of around 15% in the medium term. This outlook does not include the impact of any material acquisitions or divestments.

Adjusted EBITDA for 2023 is expected to be at least EUR 75 million, with annual Adjusted EBITDA margin thereafter expected to grow and be in the range of 14% to 16% in the medium term. The expected improvement in Adjusted EBITDA margin is expected to be primarily driven by gross profit margin optimisation, cost efficiencies and overall benefits of scale as the Azerion platform grows. This outlook does not include the impact of any material acquisitions or divestments.

Other information

Interest Bearing Debt  

Interest Bearing Debt in millions of EUR 31 December 2022 31 December 2021
Total non-current indebtedness 214.3 213.3
Total current indebtedness 12.8 11.5
Total financial indebtedness 227.1 224.8
Deduct Zero interest bearing loans (0.1) (0.7)
Interest Bearing Debt 227.0 224.1
Less: Cash and cash equivalents (50.9) (35.3)
Net Interest Bearing Debt  176.1 188.8

References to the bond terms in the table above refer to the terms as defined in the senior secured callable fixed rate bond ISIN: SE0015837794

Reconciliation of net income to Adjusted EBITDA 

Reconciliation of net income to Adjusted EBITDA In millions of EUR Q4
2022 2021
Azerion Group Premium Games Platform Other Azerion Group Premium Games Platform
Profit / (loss) for the period 14.3 (4.8)
Income Tax expense (2.3) 1.9
Profit / (loss) before tax 12.0 (2.9)
Net finance costs (3.1) 8.6
Share in profit/(loss) of joint venture (0.3)
Operating profit / (loss) 8.9 1.8 7.4 (0.3) 5.4 2.6 2.7
Depreciation & Amortization 12.1 3.3 8.7 0.1 6.7 3.4 3.4
EBITDA 21.0 5.1 16.1 (0.2) 12.1 6.0 6.1
De-SPAC related expenses 0.2 0.2
Other (1.5) 0.0 (1.4) (0.1) 4.1 0.5 3.6
Acquisition expenses 2.0 1.7 0.3 3.2 1.3 1.8
Restructuring 0.4 0.0 0.4 0.0 0.0
Adjusted EBITDA 22.1 5.1 17.0 19.4 7.8 11.5
Reconciliation of net income to Adjusted EBITDA In millions of EUR FY
2022 2021
Azerion Group Premium Games Platform Other Azerion Group Premium Games Platform
Profit / (loss) for the period (124.8) (19.9)
Income Tax expense 0.1 2.0
Profit / (loss) before tax (124.7) (17.9)
Net finance costs (4.3) 26.6
Share in profit/(loss) of joint venture (0.3)
Operating profit / (loss) (129.0) 2.1 (6.5) (124.6) 8.4 6.0 2.3
Depreciation & Amortization 38.5 12.1 26.3 0.1 24.8 10.5 14.3
EBITDA (90.5) 14.2 19.8 (124.5) 33.2 16.5 16.6
De-SPAC related expenses 135.4 2.5 9.6 123.3
Other (0.6) (0.1) (1.5) 1.0 10.3 2.0 8.2
Acquisition expenses 6.0 0.2 5.5 0.3 3.2 1.3 1.8
Restructuring 1.8 0.3 1.6 (0.1) 0.0
Adjusted EBITDA 52.1 17.1 35.0 46.7 19.8 26.6
Breakdown of operating expenses In millions of EUR Q4 FY
2022 2021 2022 2021
Personnel costs 24.8 24.2 84.5 55.1
Other expenses 9.2 15.5 52.9 33.3
Operating expenses 34.0 39.7 137.4 88.4
Of which:
Platform 27.4 30.4 94.5 63.2
Premium Games 6.7 9.3 28.3 25.2

Restructuring

As part of the process to accelerate the integration of acquired companies into Azerion Group N.V. and further realise synergies, we initiated a restructuring plan in Q1 2023 designed to continue the integration of our businesses, improving efficiency and focusing our resources on key strategic opportunities. This program is expected in aggregate to reduce our global workforce by approximately 9%, for which in aggregate charges of approximately EUR 2.1 million are expected to be recognised in the first quarter of 2023. These costs impact the reported operating profit / loss, but are removed from Adjusted EBITDA.

Background information

Legal merger

As announced on 13 January 2023, to simplify its reporting structure, Azerion merged the parent company Azerion Group N.V. and Azerion Holding B.V.. As a result, the interim unaudited results for the fourth quarter and full year 2022 relate only to the surviving entity Azerion Group N.V. In the same way, Azerion will publish one annual report for the full year 2022.

Condensed consolidated statement of profit or loss and other comprehensive income

Q4 FY
In millions of EUR 2022 2021 2022 2021
Net revenue 148.8 126.3 452.6 308.1
Costs of services & materials (95.7) (75.9) (286.3) (187.2)
Gross profit 53.1 50.4 166.3 120.9
Personnel costs (24.8) (24.2) (84.5) (55.1)
Depreciation (2.1) 0.9 (7.0) (5.3)
Amortization (9.5) (5.7) (31.0) (17.6)
Impairment of non-current assets (0.5) (1.9) (0.5) (1.9)
Other gains and losses 1.9 1.4 (119.4) 0.7
Other expenses (9.2) (15.5) (52.9) (33.3)
Operating profit / (loss) 8.9 5.4 (129.0) 8.4
Finance income 9.6 0.6 27.7 1.8
Finance costs (6.5) (9.2) (23.4) (28.4)
Net Finance costs 3.1 (8.6) 4.3 (26.6)
Share in profit/(loss) of joint venture 0.3 0.3
Profit / (loss) before tax 12.0 (2.9) (124.7) (17.9)
Income Tax expense 2.3 (1.9) (0.1) (2.0)
Profit / (loss) for the period 14.3 (4.8) (124.8) (19.9)
Attributable to:
Owners of the company 12.9 (4.6) (126.0) (19.6)
Non-controlling interest 1.4 (0.2) 1.2 (0.3)
Profit / (loss) for the period  14.3 (4.8) (124.8) (19.9)
Exchange difference on translation of foreign operations (1.3) (3.4) (2.6) 0.2
Remeasurement of net defined benefit liability
Total comprehensive income for the period 13.0 (8.2) (127.4) (19.7)
Total comprehensive (loss) / income attributable to:
Owners of the company 13.2 (8.3) (127.2) (19.4)
Non-controlling interest (0.2) 0.1 (0.2) (0.3)

Condensed consolidated statement of financial position

In millions of EUR 31 December 2022 31 December 2021
Assets
Non-current assets 440.5 323.6
Goodwill 183.9 177.3
Intangible assets 186.2 87.6
Property, plant and equipment 20.5 18.5
Non-current financial assets 37.0 35.9
Deferred tax asset 12.9 4.2
Investment in joint ventures 0.1
Current assets 210.0 140.1
Trade and other receivables1) 157.9 103.5
Current tax assets 1.2 1.3
Cash and cash equivalents 50.9 35.3
Total assets 650.5 463.7
Equity
Shareholders’ equity 84.0 (8.6)
Non-controlling interest 2.4 1.7
Total equity 86.4 (6.9)
Liabilities
Non-current liabilities 267.9 260.1
Borrowings 200.0 199.0
Lease liabilities 14.3 14.3
Provisions 0.6 0.4
Employee benefits 1.0 1.0
Deferred tax liability 41.6 29.8
Other non-current liability 10.4 15.6
Current liabilities 296.2 210.5
Borrowings 7.9 6.8
Lease liabilities 4.9 4.7
Provisions 0.9 1.0
Trade and other payables1) 223.9 141.5
Other current liabilities 50.1 53.5
Current tax liabilities 8.5 3.0
Total liabilities 564.1 470.6
Total equity and liabilities 650.5 463.7

1) Contract assets and Contract liabilities have been reclassified to Trade and other receivables and Trade and other payables to reflect the appropriate accounting treatment

Condensed consolidated statement of cash flow

Q4 FY
In millions of EUR 2022 2021 2022 2021
Cash flows from operating activities
Operating profit / (loss) 8.9 5.4 (129.0) 8.4
Adjustments for operating profit / (loss): 14.0 4.3 177.0 27.3
Changes in working capital items: 
(Increase)/Decrease in trade and other receivables (22.5) (7.2) (22.1) (2.7)
Increase (decrease) in trade payables and other payables 25.4 44.7 48.3 6.6
Utilization of provisions (1.5) (0.3) (3.1) (0.3)
Interest paid (4.7) (8.7) (18.7) (14.0)
Income tax paid 0.4 (1.1) (0.8) (1.3)
Net cash provided by (used for) operating activities excluding SARs related cash outflows 20.0 37.1 51.6 24.0
SARs related cash outflows (6.7)
Net cash provided by (used for) operating activities including SARs related cash outflows 20.0 37.1 44.9 24.0
Cash flows from investing activities
Payments for property, plant and equipment (0.1) (1.2) (1.5) (1.4)
Payments for intangibles (6.1) (5.7) (20.2) (16.7)
Decrease/ (Increase) in loans and other investments (0.7) (0.7)
Net cash outflow on acquisition of subsidiaries (8.6) (25.7) (54.1) (64.3)
Net cash provided by (used for) investing activities (14.8) (33.3) (75.8) (83.1)
Cash flows from financing activities
Proceeds from external borrowings 227.5
Transaction costs (5.7) (5.7)
Repayment of external borrowings (0.8) (3.2) (2.3) (113.8)
Increase in loans to related parties (0.5) (12.4)
Early settlement of Senior Secured Callable Floating Rate Bonds (7.7)
De-SPAC related expenses (0.3) (33.7)
Payment of principal portion of lease liabilities (2.2) (0.6) (7.6) (4.1)
Proceeds from De-SPAC transaction 404.1
Settlement of De-SPAC transaction (310.9)
Other inflows (outflows) from financing activities 0.2 0.2 (2.2) 0.2
Net cash provided by (used for) financing activities (3.1) (9.8) 47.4 84.0
Net increase in cash and cash equivalents 2.1 (6.0) 16.5 24.9
Effect of changes in exchange rates on cash and cash equivalents (0.4) 0.1 (0.9)
Cash and cash equivalents at the beginning of the period 49.2 41.2 35.3 10.4
Cash and cash equivalents at the end of the period 50.9 35.3 50.9 35.3

Breakdown of adjustments to operating profit / (loss) in consolidated statement of cashflows

Q4 FY
In millions of EUR 2022 2021 2022 2021
Adjustments for operating profit / (loss):
Depreciation and amortisation 11.6 4.8 38.0 22.9
Impairment of tangible & intangible assets 0.5 1.9 0.5 1.9
Movements in provisions per profit and loss 1.2 (2.4) 3 0.5
Share-based payments expense 0.6 0.6 13.6 1.2
De-SPAC related expenses 0.2 14.8
De-SPAC listing expense 107.1
Other non-cash items (0.6) 0.0 0.8

Definitions

Adjusted EBITDA means in respect of the period the consolidated profit from ordinary activities according to the latest Financial Report(s):

  1. before deducting any amount of tax on profits, gains or income paid or payable by any subsidiary;
  2. before deducting any Net Finance Costs;
  3. before taking into account any extraordinary items and any non-recurring items which are not in line with the ordinary course of business;
  4. before taking into account any Transaction Costs;
  5. not including any accrued interest owing to any subsidiary;
  6. before taking into account any unrealised gains or losses on any derivative instrument (other than any derivative instruments which are accounted for on a hedge account basis);
  7. after adding back or deducting, as the case may be, the amount of any loss or gain against book value arising on a disposal of any asset (other than in the ordinary course of trading) and any loss or gain arising from an upward or downward revaluation of any asset;
  8. after adding back any amount attributable to the amortisation, depreciation or impairment of fixed assets

Adjusted EBITDA Margin means Adjusted EBITDA as a percentage of Net revenue

Average number of digital ads sold per month (paid impressions) represents the number of digital advertisements displayed to users of game and non-game content. The numbers reported do not include volumes from past acquisitions that are not yet fully integrated. As of this quarter, the reported numbers include the following previous acquisitions: advertising auction platforms Improve Digital, Admoove, Delta Projects and Infinia, as well as publisher monetisation services Headerlift, Pubgalaxy, Sublime, Inskin, Strossle, Keymobile, Madvertise and Quantum.

Average gross revenue per million processed ad requests from the advertising auction platform is calculated by dividing gross advertising revenue by a million of advertisement requests running through advertising auction platform Improve Digital. Not all advertisement requests are processed and become eligible to be fulfilled as an advertisement sold, therefore this metric measures our efficiency and overall profitability of the digital advertising auction platform, demonstrating that the revenue generated by the advertisements that are sold also remunerate and more than cover the costs of all the advertisement requests.

Average time in game per day measures how many minutes per day, on average, the players of Premium Games spend in our games. This demonstrated their engagement with the games, which generates more opportunities to grow the ARPDAU.

Average DAUs means average daily active users, which is the number of distinct users per day averaged across the relevant period.

ARPDAU means Average Revenue per Daily Active User, which is revenue per period divided by days in the period divided by average daily active users in that period and represents average per user in-game purchases for the period.

EBIT means, in respect of the period, the consolidated profit from ordinary activities according to the latest Financial Report(s):

  1. before deducting any amount of tax on profits, gains or income paid or payable by any member of the Group;
  2. before deducting any Net Finance Costs

EBITDA means in respect of the period the consolidated profit from ordinary activities according to the latest Financial Report(s):

  1. before deducting any amount of tax on profits, gains or income paid or payable by any subsidiary;
  2. before deducting any Net Finance Costs;
  3. before deducting any amount attributable to the amortisation, depreciation, or impairment of fixed assets

Financial Indebtedness means as defined in the terms and conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794 any indebtedness in respect of:

  1. monies borrowed or raised. including Market Loans;
  2. the amount of any liability in respect of any Finance Leases;
  3. receivables sold or discounted (other than any receivables to the extent they are sold on a non-recourse basis);
  4. any amount raised under any other transaction (including any forward sale or purchase agreement) having the commercial effect of a borrowing;
  5. any derivative transaction entered into in connection with protection against or benefit from fluctuation in any rate or price (and, when calculating the value of any derivative transaction, only the mark to market value shall be taken into account, provided that if any actual amount is due as a result of a termination or a close-out, such amount shall be used instead);
  6. any counter indemnity obligation in respect of a guarantee, indemnity, bond, standby or documentary letter of credit or any other instrument issued by a bank or financial institution; and
  7. (without double counting) any guarantee or other assurance against financial loss in respect of a type referred to in the above paragraphs (a)-(f).

Gross Profit Margin means Gross Profit as a percentage of Net revenue

Gross Profit means the profit made after subtracting from Net revenue all (variable) costs that are related to manufacturing of its products or services.

Net Interest Bearing Debt as defined in the terms and conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794 means the aggregate interest bearing Financial Indebtedness less cash and cash equivalents of Azerion Group N.V. and its subsidiaries from time to time in accordance with the Accounting Principles (for the avoidance of doubt, excluding any Bonds owned by the Issuer, guarantee, bank guarantees, Subordinated Loans, any claims subordinated pursuant to a subordination agreement on terms and conditions satisfactory to the Agent and interest-bearing Financial Indebtedness borrowed from any Azerion Group Company) as such terms are defined in the terms and conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794

Operating expenses are defined as the aggregate of personnel costs and other expenses as reported in the statement of Other comprehensive income. More details on the cost by nature reporting can be found in the published annual financial statements of 2021.

Transaction Costs means all fees, costs and expenses, stamp, registration and other taxes incurred by Azerion Group in connection with (i) the Bond Issue, (ii) any Subsequent Bond Issue, (iii) the listing of the Bonds or any Subsequent Bonds, (iv) acquisitions, mergers and divestments of companies and (v) an Equity Listing Event, as such terms are defined in the terms and conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794

Disclaimer and Cautionary Statements

This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

This communication may include forward-looking statements. All statements other than statements of historical facts are, or may be deemed to be, forward-looking statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Azerion to market risks and statements expressing management’s expectations, beliefs, estimates, forecasts, projections and assumptions. Words and expressions such as aims, ambition, anticipates, believes, could, estimates, expects, goals, intends, may, milestones, objectives, outlook, plans, projects, risks, schedules, seeks, should, target, will or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks, uncertainties and other factors that are difficult to predict and that could cause the actual results, performance or events to differ materially from future results expressed or implied by such forward-looking statements contained in this communication. Readers should not place undue reliance on forward-looking statements.

Any forward-looking statements reflect Azerion’s current views and assumptions based on information currently available to Azerion’s management. Forward-looking statements speak only as of the date they are made and Azerion does not assume any obligation to update or revise such statements as a result of new information, future events or other information, except as required by law.

The interim financial results of Azerion Group N.V. as included in this communication are required to be disclosed pursuant to the terms and conditions of the Senior Secured Callable Fixed Rate Bonds ISIN: SE0015837794.

This report has not been reviewed or audited by Azerion’s external auditor.

Certain financial data included in this communication consist of alternative performance measures (“non-IFRS financial measures”), including EBITDA and Adjusted EBITDA. The non-IFRS financial measures, along with comparable IFRS measures, are used by Azerion’s management to evaluate the business performance and are useful to investors. They may not be comparable to similarly titled measures as presented by other companies, nor should they be considered as an alternative to the historical financial results or other indicators of Azerion Group N.V.’s cash flow based on IFRS. Even though the non-IFRS financial measures are used by management to assess Azerion Group N.V.’s financial position, financial results and liquidity and these types of measures are commonly used by investors, they have important limitations as analytical tools, and the recipients should not consider them in isolation or as a substitute for analysis of Azerion Group N.V.’s financial position or results of operations as reported under IFRS.

For all definitions and reconciliations of non-IFRS financial measures please also refer to www.azerion.com/investors.

This report may contain forward-looking non-IFRS financial measures. We are unable to provide a reconciliation of these forward-looking non-IFRS financial measures to the most comparable IFRS financial measures because certain information needed to reconcile those non-IFRS financial measures to the most comparable IFRS financial measures is dependent on future events some of which are outside the control of Azerion. Moreover, estimating such IFRS financial measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-IFRS financial measures in respect of future periods which cannot be reconciled to the most comparable IFRS financial measure are calculated in a manner which is consistent with the accounting policies applied in Azerion Group N.V.’s consolidated financial statements.

This communication does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or any other financial instruments.

Contact

Investor Relations: ir@azerion.com

Media relations: press@azerion.com

GlobeNewswire Distribution ID 1000795143

Azerion to propose cancellation of shares held in treasury

Amsterdam, 28 February 2023 – Today, Azerion has announced its intention to cancel up to 58,690,961 ordinary shares held in treasury, in order to reduce the number of shares outstanding. A resolution for the cancellation of the treasury shares will be submitted at the next Annual General Meeting (AGM), which is scheduled for 15 June 2023.

Atilla Aytekin, co-CEO of Azerion, comments: “Since the listing Azerion has matured significantly in its operations and performance. The company’s success during a challenging macro environment supports our belief in the fundamental growth of our business. These developments allow us to use our cash flow to fund future growth and be less reliant on equity as a form of M&A currency going forward.”

The resolution to the AGM will propose that 3,000,000 million shares are left in treasury for the purpose of employee stock options and earn outs from previous acquisitions. Currently Azerion has a total of 61,690,961 shares held in treasury, from a total of 181,561,748 outstanding shares.

Once the treasury shares are cancelled, the proposed ordinary shares outstanding in Azerion N.V. can be summarised as followed (based on current number of shares held in treasury):

Share summary table
Ordinary Shares (excl. Treasury) 119,870,787
Ordinary Shares in Treasury 3,000,000
Total Ordinary Shares 122,870,787

About Azerion

Azerion is a high-growth digital entertainment and media platform. As a content-driven, technology and data company, Azerion serves consumers, digital publishers, advertisers, and game creators globally. Azerion’s integrated platform provides technology solutions to automate the purchase and sale of digital advertising for media buyers and sellers, supported by in-market sales and campaign management teams. Through our technology, content creators, digital publishers and advertisers work with Azerion to reach the millions of people across the globe that play Azerion’s games and view its distributed entertainment content to increase engagement, loyalty, and drive e-commerce.

Founded in 2014 by two Dutch entrepreneurs, Azerion has experienced rapid expansion driven by organic growth and strategic acquisitions. Azerion is headquartered in Amsterdam, the Netherlands and is a publicly traded company listed on Euronext Amsterdam.

For more information visit: www.azerion.com

Contact
Investor Relations
ir@azerion.com

Media
press@azerion.com

DISCLAIMER
The companies in which Azerion Group N.V. directly and indirectly owns investments are separate legal entities. In this announcement “Azerion”, “Azerion Group” and “Group” are sometimes used for convenience where references are made to Azerion Group N.V. and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Azerion Group N.V. and its subsidiaries in general or to those who work for them.

This press release is for information purposes only. The information contained in this press release does not purport to be full or complete and, in particular, is not intended to form the basis of any investment decision. No reliance may be placed by any person for any purpose on the information contained in this press release or its accuracy, fairness or completeness. Azerion will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided.

This press release may include forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as believes, estimates, plans, projects,
anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause the actual results of Azerion to differ materially from future results expressed or implied by such forward-looking statements. Any forward-looking statements reflect Azerion’s current views and assumptions based on information currently available to Azerion’s management. Forward-looking statements speak only as of the date they are made, and Azerion does not assume any obligation to update such statements, except as required by law. No assurances can be given that the forward-looking statements will be realised. No representation or warranty is made that any of these forward-looking statements will come to pass or that any estimated result will be achieved. Accordingly, no undue reliance should be placed on any forward-looking statements.

GlobeNewswire Distribution ID 1000795140

Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies

SHANGHAI, China, Feb. 27, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the successful completion of two randomized, double-blind, placebo-controlled, multi-center phase III clinical studies (Study nos.: JS002-003 and JS002-006) evaluating the company’s product ongericimab (a recombinant humanized anti-PCSK9 monoclonal antibody, product code: JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, and both studies have met their primary endpoints.

According to the Report on Cardiovascular Health and Diseases in China (2021), in recent years, both the blood lipid levels and the prevalence of dyslipidemia of the Chinese population have been on the rise, and dyslipidemia affects up to 40.4% of adults. Dyslipidemia, specifically the increase of low-density lipoprotein cholesterol (“LDL-C”), is the most important independent risk factor for atherosclerotic cardiovascular diseases (“ASCVDs”). The growing prevalence of dyslipidemia underscores the urgent need for effective treatments to lower LDL-C levels, which can significantly lower the incidence of ASCVDs and the risk of death.

At present, the awareness, treatment, and control rates of dyslipidemia in adults in China are all relatively low. The current lipid-lowering treatment and compliance rates among individuals at high or extremely high risk of ASCVDs are concerning, and there remains a relatively significant unmet clinical demand for lipid-lowering treatments. As a new lipid-lowering drug that effectively reduces LDL-C levels, PCSK9 inhibitors have been recommended in both Chinese and overseas dyslipidemia management guidelines, and are widely recognized by clinicians. Unfortunately, there are only two imported ant-PCSK9 monoclonal antibodies currently approved for marketing in China, and no domestic anti-PCSK9 monoclonal antibody has been approved for marketing.

Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by Junshi Biosciences. Two major pivotal registered clinical studies (Study nos.: JS002-003 and JS002-006) of ongericimab have been successfully completed and met their primary endpoints. The JS002-003 study assessed the effectiveness and safety of subcutaneous injection of ongericimab for the treatment of patients with primary hypercholesterolemia and mixed dyslipidemia, while the JS002-006 study assessed the effectiveness and safety of subcutaneous injection using two drug delivery systems (pre-filled syringes and pre-filled automatic syringes) of ongericimab for the same indications. Ongericimab exhibited significant lipid-lowering efficacy in both studies with good safety.

“The emergence of PCSK9 inhibitors has provided better treatment options for dyslipidemia patients, particularly those at high or extremely risk of ASCVD,” said Academician Yaling HAN from the General Hospital of Northern Theatre Command. “The positive results of ongericimab’s phase III clinical trials are very encouraging and show comparable efficacy and safety to similar PCSK9 inhibitors from overseas. We look forward to the launch of ongericimab to address unmet medical needs, and we hope the incidence and mortality of cardiovascular disease could decrease in China.”

“I’m pleased to see a Chinese-developed anti-PCSK9 monoclonal antibody delivering such outstanding lipid-lowering outcomes,” said Professor Shuiping ZHAO from the Second Xiangya Hospital of Central South University. “This will equip our clinicians with more lipid-lowering treatment options and benefit countless patients in China. The management of the Chinese population’s blood lipid levels requires continuous improvement, and we expect ongericimab to contribute greatly to this process.”

“I’m excited to witness the simultaneous success of two phase III studies examining ongericimab,” said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. “These achievements were only possible through the joint efforts and dedication of researchers, patients, and R&D teams. With China entering an aging society, we hope that ongericimab can provide additional treatment options for hyperlipidemia patients and address unmet medical needs.”

About Ongericimab (JS002)

Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody independently developed by Junshi Biosciences for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. Junshi Biosciences is the first company in China to obtain clinical trial approval for the target drug. The company has completed Phase III clinical studies in patients with primary hypercholesterolemia and mixed hyperlipidemia, and Phase II clinical studies in patients with homozygous familial hypercholesterolemia. The enrollment of patients for Phase III clinical studies of heterozygous familial hypercholesterolemia has been completed.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8778033

Dr. Vinson Eugene Allen Honored and Celebrated as One of California’s Most Influential Medical Pioneers for Black History Month

First African American to open a chain of free-standing fully functional urgent care facilities in the state of California.

Dr. Vinson Eugene Allen

Dr. Vinson Eugene Allen

LOS ANGELES, Feb. 27, 2023 (GLOBE NEWSWIRE) — Dr. Vinson Eugene Allen is being honored and celebrated for Black History Month as one of California’s most influential medical pioneers. Dusk to Dawn Urgent Care Los Angeles reports, Ombudsman international and Bulletin Displays of Los Angeles have begun a billboard campaign throughout Southern California celebrating the medical veteran and his accomplishments throughout the state. In 2001, Dr. Vinson Eugene Allen began a journey to serve the underserved communities in Los Angeles and Orange County. The Doctors vision was to open a chain of urgent care facilities to serve the diverse, multicultural community. Dr. Allen became the first African American to open a chain of free-standing, fully functional urgent care facilities in California. Leaving a blueprint for future leaders to emulate.

Dusk to Dawn Urgent Care and The Saint Vinson Eugene Allen Foundation are known for giving back to the community and have sponsored some of Los Angeles’s largest charity events. Their organizations provide year-round free medical care to the underserved, including the homeless. Dr. Vinson Eugene Allen, sponsors the Compton Cancer Awareness Program, the Los Angeles Holiday Annual 1000 Turkey and Toy giveaway. In 2022, the organization gave away four Cars and hundreds of Gas cards nationwide to people in need.

Dr. Allen states: “History should inspire you; it should leave you with a sense of great honor and pride. I hope when others look back on this achievement, they feel this energy.”

In February of 2022, during Black History Month, Dr. Vinson Eugene Allen made world headlines as he achieved the Guinness World Records title for the world’s tallest 3D-printed sculpture of a Human. Last month, the Foundation and Dr. Allen announced its commitment to special needs children with the $50,000 Hand-Up Award, designed to help families nationwide, named in honor of son Colin Mathew Allen, who has autism.

Dr. Vinson Eugene Allen is the founder of Dusk to Dawn Urgent Care and Corona Virus Test Los Angeles facilities, located throughout Southern California. For 20 years, Dr. Vinson Eugene Allen and his wife, Dr. Connie Yu Allen, have centered their commitment on servicing Los Angeles County and the surrounding communities. The Saint Vinson Eugene Allen Foundation has been a legendary pillar in the community during tough times. Dr. Vinson Eugene Allen ran as a candidate in the 2022 race for California State Insurance Commissioner in the June primary.

Contact

Website: www.dusktodawnurgentcare.com
Website: www.saintvinsoneugeneallen.com
Social Media: @DrAllenLa
YouTube: Conversations with Dr. Allen
YouTube: AllenFamilyUnity
Website: www.coronavirustestla.com

Contact Information:
Derrick Dzurko
Press Agent
derrick@e1mgmedia.com
(888) 231-6942

Related Images

Image 1: Dr. Vinson Eugene Allen

Image 2: Dr. Vinson Eugene Allen & Family

Los Angeles MLK Parade in 2023. 16th & Broadway Entertainment.

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8777859